I am keeping a close eye on (Nasdaq: IXHL) (ASX: IHL) as they announce the progress of their Phase 2 trial, PsiGAD1, for the treatment of generalised anxiety disorder (GAD) using psilocybin-assisted psychotherapy. The trial has achieved its interim milestone of 29 patients completing primary endpoint assessments and independent analysis of the interim study data has begun. With the potential for a promising treatment for GAD, where current medications and therapies are inadequate, I am bullish on the stock's performance. I see a nice steady run to $0.26 and a re-test of $0.22.5 in the near future. However, as always, it's important to do one's own research and stick to one's trading/ Invesment plan. 100% its a long hold for me ...
- Forums
- ASX - By Stock
- IHL
- Ann: Independent data review commences for Ph 2 trial psilocybin
Ann: Independent data review commences for Ph 2 trial psilocybin, page-20
-
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online